Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.

Hifumi, Toru; Isokawa, Shutaro; Otani, Norio; Ishimatsu, Shinichi

Hifumi, Toru; Isokawa, Shutaro; Otani, Norio; Ishimatsu, Shinichi.

Afiliação

Hifumi T; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan. hifumitoru@gmail.com.
Isokawa S; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Otani N; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
Ishimatsu S; Department of Emergency and Critical Care Medicine, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.

Crit Care ; 24(1): 497, 2020 08 12.

Article em En | MEDLINE | ID: mdl-32787901

Assuntos

Infecções por Coronavirus; Estado Terminal; Pandemias; Pneumonia Viral; Amidas; Benzamidinas; Betacoronavirus; COVID-19; Guanidinas; Humanos; Pirazinas; SARS-CoV-2

Palavras-chave

Adverse events; COVID-19; Favipiravir; Nafamostat mesylate

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Estado Terminal / Infecções por Coronavirus / Pandemias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Crit Care Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google